Gastrointestinal Langerhans cell histiocytosis responding to cladribine and imatinib mesylate
Gastrointestinal involvement in Langerhans cells histiocytosis (LCH) is extremely rare. An optimal treatment regimen is not defined yet and its prognosis is relatively poor. Cladribine, and more recently, Imatinib mesylate (IM) have been recommended as treatment options in refractory LCH. Here we pr...
| Autores principales: | , , , , |
|---|---|
| Formato: | Artículo |
| Lenguaje: | inglés |
| Publicado: |
UANL Facultad de Medicina
2010
|
| Acceso en línea: | http://eprints.uanl.mx/8449/1/Gastrointestinal%20Langerhans.pdf |
| Sumario: | Gastrointestinal involvement in Langerhans cells histiocytosis (LCH) is extremely rare. An optimal treatment regimen is not defined yet and its prognosis is relatively poor. Cladribine, and more recently, Imatinib mesylate (IM) have been recommended as treatment options in refractory LCH. Here we present a case of gastrointestinal involvement in an adult patient with LCH refractory to several treatment regimens who responded nicely to cladribine and currently treated with IM 300 mg/day, as maintenance, for the last 24 months. |
|---|